Lantheus Announces Leadership Transition Plan

Core Viewpoint - Lantheus Holdings, Inc. announces the retirement of CEO Brian Markison effective December 31, 2025, after over 13 years of service, with Mary Anne Heino appointed as Executive Chairperson and interim CEO during the transition period [1][2]. Leadership Transition - Brian Markison will retire as CEO, and the Board is conducting a search for his successor, while he will serve as a strategic advisor until at least March 31, 2026 [1]. - Mary Anne Heino, previously CEO from 2015 to 2024, will take on the role of Executive Chairperson and interim CEO following Markison's retirement [2]. Management Changes - Paul Blanchfield, the President of Lantheus, is leaving the company for another role, and Heino and Markison will collaborate to cover his responsibilities [3]. - Amanda Morgan will return from leave to continue her role as Chief Commercial Officer, reporting directly to Heino [3]. Company Performance and Strategy - Under Markison's leadership, Lantheus made strategic acquisitions, including Evergreen Theragnostics and Life Molecular Imaging, diversifying revenue streams and enhancing its development pipeline [4]. - The company is positioned for future growth with multiple potential FDA market approvals and a strong pipeline of diagnostic and therapeutic candidates [4]. Executive Insights - Julie McHugh, Lead Independent Director, expressed gratitude for Markison's leadership and contributions, emphasizing the company's commitment to a smooth transition [4]. - Heino highlighted her excitement to lead during this transition and focus on commercial execution and upcoming product approvals, including a new formulation of their PSMA PET imaging agent [4]. Company Background - Lantheus is a leading radiopharmaceutical-focused company with nearly 70 years of experience, dedicated to improving patient outcomes through innovative solutions [8].